ClinicalTrials.gg
TerminatedNCT03894020Updated Oct 30, 2024

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

An observational study in Dry Age-related Macular Degeneration, Macular Degeneration and Retinal Disease, sponsored by Gyroscope Therapeutics Limited. Terminated at 71 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-30.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's listed conditions name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gyroscope Therapeutics Limited · Observational

Why this study was terminated
The study was terminated due to the interim analysis demonstrating lack of treatment efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
83
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Enrollment
16th of 24
83 · median 138
Started
2019
with 8 others
Observational
24 of 131
7 open now
Registered
60th of 131
by date
Lead sponsor
5 of 131
Gyroscope Therapeutics Limited

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 16th largest by enrollment of the 24 observational ones that give a count, is one of 9 that started in 2019, is one of 24 observational ones, and was the 60th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

Read the detailed description

Prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA due to AMD.

03

Conditions studied

  • Dry Age-related Macular Degeneration
  • Macular Degeneration
  • Retinal Disease
  • Retinal Degeneration
  • Geographic Atrophy
  • Macular Atrophy
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's enrollment of 83 is below the median of 130 across 39 observational studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Gyroscope Therapeutics Limited is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Secondary care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD)
  2. BCVA of 40 letters or better using ETDRS charts

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic retinopathy
  2. Significant ocular or non-ocular disease that would impact the subject's ability to participate in the study
  3. Participation in another research study involving an product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline OR received a gene/cell therapy at any time previously
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
83 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Geographic Atrophy (GA)

    Change from baseline in area of Geographic Atrophy, as assessed by Fundus Auto Fluoresence measured in mm2

    Time frame: Up to 96 weeks

  2. Colour Fundus (CF)

    Change from baseline in Colour Fundus Photography measured in mm2

    Time frame: Up to 96 weeks

  3. Retinal Drusen Volume

    Change from baseline in retinal drusen volume measured in mm3

    Time frame: Up to 96 weeks

  4. Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA)

    Change from baseline in ETDRS BCVA reading score

    Time frame: Up to 96 weeks

  5. Retinal sensitivity

    Change from baseline in retinal sensitivity as assessed by microperimetry

    Time frame: Up to 96 weeks

  6. Visual Functioning Questionnaire

    Change from baseline in National Eye Institute Visual Functioning Questionnaire 25-Items Version (NEI VFQ-25) Minimum Score (Best) = 29. Maximum score (Worst) = 149

    Time frame: Up to 96 weeks

  7. Medical Events of Interest (MEI)

    Change from baseline in percentage of Participants with MEI

    Time frame: Up to 96 weeks

  8. Monocular and Binocular Reading Performance

    Change in Monocular and Binocular Reading Performance measured in words/min

    Time frame: Up to 96 weeks

08

Study locations

71 sites
  • Retinal Research Institute (retina consultants of AZ)
    Phoenix, Arizona 85053, United States
  • Retina Centers PC
    Tucson, Arizona 85704, United States
  • Retina Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • Byers Eye Institute at Stanford
    Palo Alto, California 94303, United States
  • Retina Health Center
    Fort Myers, Florida 33907, United States
  • Retina Vitreous Associates of Florida
    Saint Petersburg, Florida 33711, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina PC
    Marietta, Georgia 30060, United States
  • University Retina Macula Associates PC
    Lemont, Illinois 60452, United States
  • Midwest Eye Institute Northside
    Indianapolis, Indiana 46290, United States
  • Wolfe Eye Clinic
    West Des Moines, Iowa 50266, United States
  • The Retina Care Center
    Baltimore, Maryland 21209, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • Ophthalamic Consultants of Boston (OCB)
    Boston, Massachusetts 02114, United States
  • Pepose Vision Institute
    Chesterfield, Missouri 63017, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • New Jersey Retina Research Foundation
    Vauxhall, New Jersey 07088, United States
  • Long Island Vitreoretinal Consultants
    Great Neck, New York 11021, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Retina Association of Western New York
    Rochester, New York 14620, United States
  • Wake Forest Baptist Medical Center - Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Eye Institute
    Cincinnati, Ohio 45242, United States
  • Casey Eye Institute - OHSU
    Portland, Oregon 97239, United States
  • Mid-Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Retina Consultants of Houston-TMC
    Bellaire, Texas 77401, United States
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
  • Retina Consultants of Houston
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah
    Salt Lake City, Utah 84107, United States
  • Proliance Retina (formally known as Vitreoretinal Associates of Washington)
    Bellevue, Washington 98004, United States
  • Retina Center Northwest
    Silverdale, Washington 98383, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • The University of Melbourne - The Centre for Eye Research Australia (CERA)
    East Melbourne, 3002, Australia
  • Lions Eye Institute (LEI) - Nedlands
    Nedlands, 6009, Australia
  • Centre Ophtalmologique Retine Gallien
    Bordeaux, 33000, France
  • Centre Hospitalier Intercommunal Creteil
    Créteil, 94000, France
  • CHU Dijon - Hôpital Mitterrand
    Dijon, 2100, France
  • Hopital de la Croix Rousse - GH Nord
    Lyon, 69004, France
  • Centre Paradis Monticelli
    Marseille, 13008, France
  • Centre Hospitalier Universitaire de Nantes (CHU de Nantes) - Hotel-Dieu
    Nantes, 44093, France
  • Hopital Lariboisiere
    Paris, 75010, France
  • Centre Hospitalier Universitaire de Poitiers - Poitiers University Hospital
    Poitiers, 86021, France
  • EyeNet Baden-Wuerttemberg
    Freiburg, 79106, Germany
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • University Hospital Schleswig-Holstein - Campus Luebeck
    Lübeck, 23538, Germany
  • Klinikum rechts der Isar der Technische Universitaet Muenchen
    Munich, 81675, Germany
  • St. Franziskus-Hospital
    Münster, 48145, Germany
  • MVZ ADTC Siegburg GmbH
    Siegburg, 53721, Germany
  • Augenklinik Sulzbach
    Sulzbach, 66280, Germany
  • Universitaetsklinikum Tuebingen
    Tübingen, 72076, Germany
  • Amsterdam UMC - Locatie AMC
    Amsterdam, 1105, Netherlands
  • Radboud Universitair Medisch Centrum
    Nijmegen, 6525, Netherlands
  • Okulistyczna "Jasne Blonia" Sp. z o.o.
    Łódź, Rojna 91-134, Poland
  • Specjalistyczny Osrodek Okulistyczny Oculomedica
    Bydgoszcz, 85-316, Poland
  • Oftalmika - Prywatna Klinika Okulistyczna
    Bydgoszcz, 85-631, Poland
  • Caminomed
    Tarnowskie Góry, 42-600, Poland
  • Instituto de microcirugía ocular
    Barcelona, 08035, Spain
  • Hospital General de Catalunya Sant Cugat del Valles
    Barcelona, 08915, Spain
  • VISSUM Mirasierra
    Madrid, 28035, Spain
  • Hospital Clinico San Carlos
    Madrid, 28040, Spain
  • Clinica Universidad de Navarra - Pamplona
    Pamplona, 31008, Spain
  • Burnley General Hospital
    Burnley, BB10 2PQ, United Kingdom
  • NHS Greater Glasgow and Clyde
    Glasgow, G12 0YN, United Kingdom
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7TF, United Kingdom
  • Retina Clinic London
    London, W1G 7LB, United Kingdom
  • Manchester Royal Eye Hospital
    Manchester, M13 9WL, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
  • Salisbury NHS Foundation Trust
    Salisbury, SP2 8BJ, United Kingdom
  • Southampton General Hospital
    Southampton, SO16 6YD, United Kingdom
  • Sunderland Eye Infirmary
    Sunderland, SR2 9HP, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Mar 2024, 62 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2019
First posted
Mar 28, 2019
StartActual
Jan 8, 2019
Primary completionActual
Mar 25, 2024
CompletionActual
Mar 25, 2024
Last update
Oct 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03894020
Lead sponsor
Gyroscope Therapeutics Limited
Responsible party
Sponsor
First posted
Mar 28, 2019
Start date
Jan 8, 2019
Primary completion
Mar 25, 2024
Completion
Mar 25, 2024
Last update
Oct 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion